Samir Undevia is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
120 Spalding Dr Ste 111
Naperville, IL 605406766
Telephone
630-646-2273Provider last certified this registry record 29 Apr 2026.
Clinical trials
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Sponsor: Pharmacyclics LLC.
- Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Sponsor: Pharmacyclics LLC.
- Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARRAY BIOPHARMA INCProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44.6%Aromatase Inhibitor25.9%Anastrozole86%Letrozole15%Part D<11 patientsEstrogen Agonist/Antagonist5.1%Tamoxifen Citrate100%Part D≥17 patients+ 6 more classes in this area
Blood & clotting
26.8%Factor Xa inhibitor25.4%Eliquis63%Xarelto37%Part D≥34 patientsVitamin K antagonist1.4%Warfarin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
11.7%Potassium supplement5.9%Potassium Chloride100%Part D<11 patientsCorticosteroid3.9%Prednisone100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”